The costs of managing advanced colorectal cancer: A broad perspective

Anti-Cancer Drugs

Volumn 8, Issue SUPPL. 2, 1997, Pages

  Kerr, David J ^a   O'Connor, Kathrine M ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Cost; Raltitrexed; Regimens; Tomudex

Indexed keywords

FLUOROURACIL; METHOTREXATE; RALTITREXED;

COLORECTAL CANCER; CONFERENCE PAPER; COST; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HOSPITAL COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PALLIATIVE THERAPY; PRIORITY JOURNAL;

EID: 0030865996     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708002-00005     Document Type: Conference Paper

References (17)

1. Rice DP, Hodgson TA, Capell F: The economic burden of cancer. In Cancer care and cost: DRGs and beyond. Edited by Scheffler RM, Andrews NC. Ann Arbor, Michigan: Health Administration Press; 1989:39-59.
2. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ: Current and future costs of cancer. Eur J Cancer 1994, 30A:60-65.
3. Department of Health: The Health of the Nation. London: Chief Medical Officer's Report 1523, HMSO; 1989.
4. Brown ML: The national economic burden of cancer: an update. J Natl Cancer Inst 1990, 82:1811-1814.
5. Bailes JS: The economics of cancer care. Cancer 1995, 76 (suppl):1886-1887.
6. Torfs K, Pocceschi S: Economic issues in advanced colorectal cancer. Eur J Cancer 1996, 32A (suppl 5):S28-S31.
7. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 304:752-755.
8. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896-903.
9. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 1994, 330:1136-1142.
10. Williams C, Coyle D, Gray A, et al.: European School of Oncology Advisory report to the Commission of the European Communities for the 'Europe Against Cancer Programme' cost effectiveness in cancer care. Eur J Cancer 1995, 31A:1410-1424.
11. Glimelius B, Hoffman K, Graf W, et al.: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995, 6:267-274.
12. Delfino C, Bosch B, Caccia G: Cost effectiveness of palliative care for advanced colorectal carcinoma [abstract 942]. In Proceedings of the American Society of Clinical Oncology. Edited by Leventhal B. Alexandria, Virginia: American Society of Clinical Oncology; 1996.
13. Kerr D: 'Tomudex' (ZD1694), a new direct and specific thymidylate synthase inhibitor, has resource saving implications in the management of colorectal cancer [abstract]. Qual Life Res 1995, 4:576.
14. Ross P, Heron J, Cunningham D: Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996, 32A (suppl 5):S13-S17.
15. Summerhayes M, Wanklyn SJ, Shakespeare RA, Lovell J: Reduced pharmacy resource utilisation associated with raltitrexed treatment of advanced colorectal cancer. J Pharm Pharmacol 1997 (in press).
16. Elliott R: An analysis of drug costs for the management of chemotherapy-related side-effects in advanced colorectal cancer. J Pharm Pharmacol 1996, 2:186-190.
17. Calman K: A Policy Framework For Commissioning Cancer Services: A Report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. London: Department of Health; 1995.